Minimally invasive cytoreductive radical prostatectomy, exploring the safety and feasibility of a single-port or multi-port robotic platform

Table 3 Adjuvant therapies in the multi-port and single-port cohorts following cytoreductive radical prostatectomy

		Surgery type
Adjuvant therapy	Overall (n = 24)	Single-port (n = 7)	Multi-port (n = 17)
ADT, No. (%)	19 (79)	6 (86)	13 (77)
Systemic chemotherapy, No. (%)	1 (4)	0 (0)	1 (6)
Radiation therapy, No. (%)	1 (4)	2 (29)	8 (47)
CYP17A inhibitor, No. (%)	2 (8)	2 (29)	6 (35)
Androgen signaling inhibitor, No. (%)^a	1 (4)	0 (0)	5 (29)

ADT androgen deprivation therapy
^aAndrogen signaling inhibitors include bicalutamide, darolutamide, and enzalutamide

ISSN: 1471-2490